erlotinib hydrochloride has been researched along with panobinostat in 2 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (panobinostat) | Trials (panobinostat) | Recent Studies (post-2010) (panobinostat) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 678 | 95 | 593 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | panobinostat (IC50) |
|---|---|---|---|
| Histone deacetylase 8 | Schistosoma mansoni | 0.45 | |
| Histone deacetylase 3 | Homo sapiens (human) | 0.2031 | |
| Bromodomain-containing protein 4 | Homo sapiens (human) | 0.005 | |
| Cytochrome P450 3A5 | Homo sapiens (human) | 0.0033 | |
| Histone deacetylase 4 | Homo sapiens (human) | 0.3792 | |
| Histone deacetylase 1 | Homo sapiens (human) | 0.181 | |
| Histone deacetylase 7 | Homo sapiens (human) | 0.9434 | |
| Histone deacetylase 2 | Homo sapiens (human) | 0.2527 | |
| Polyamine deacetylase HDAC10 | Homo sapiens (human) | 0.007 | |
| Histone deacetylase 11 | Homo sapiens (human) | 0.8396 | |
| Histone deacetylase 8 | Homo sapiens (human) | 0.46 | |
| Histone deacetylase 6 | Homo sapiens (human) | 0.2307 | |
| Histone deacetylase 9 | Homo sapiens (human) | 0.5825 | |
| Histone deacetylase 5 | Homo sapiens (human) | 0.3424 | |
| Histone deacetylase | Plasmodium falciparum (malaria parasite P. falciparum) | 0.0025 | |
| Nuclear receptor corepressor 2 | Homo sapiens (human) | 0.002 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akar, A; Altiok, S; Bepler, G; Chiappori, A; Gray, JE; Haura, E; Kish, JA; Kreahling, J; Lush, R; Neuger, A; Pinder-Schenck, M; Schell, MJ; Tanvetyanon, T; Tetteh, L; Williams, CC; Zhao, X | 1 |
| Greve, G; Lübbert, M; Pantic, M; Pfeifer, D; Schiffmann, I; Schüler, J | 1 |
1 trial(s) available for erlotinib hydrochloride and panobinostat
| Article | Year |
|---|---|
A phase I, pharmacokinetic, and pharmacodynamic study of panobinostat, an HDAC inhibitor, combined with erlotinib in patients with advanced aerodigestive tract tumors.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Panobinostat; Quinazolines; Treatment Outcome | 2014 |
1 other study(ies) available for erlotinib hydrochloride and panobinostat
| Article | Year |
|---|---|
The pan-HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR-mutated and -wildtype non-small cell lung cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Genes, erbB-1; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Lung Neoplasms; Mutation; Oligonucleotide Array Sequence Analysis; Panobinostat | 2015 |